Biosimilars Gain Ground in Turkish Patients with RA and axSpA
Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.
Biosimilar use accounts for about one in five biologic prescriptions for arthritis patients, with higher use seen in later lines of treatment and among women and those with longer disease duration, according to a Turkish study published in Nature in August 2025.
About axSpA and RA
Axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA) are long-term inflammatory diseases that often need ongoing, specific treatments.
- AxSpA often causes persistent back pain in young adults and may affect up to 1% of US adults, or roughly 2.7 million people.
- RA occurs when the immune system attacks the lining of the joints, leading to pain and swelling, commonly in the hands, knees, and ankles, and can affect other organs.
About 1.5 million Americans live with RA, which is more common in women and typically develops in middle age.
No direct quote available in the given text.
Author's summary: Biosimilars improve access to arthritis treatment in Turkey.